Hims & Hers Health, Inc. (NYSE:HIMS) Receives Average Recommendation of “Hold” from Brokerages

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have been given an average recommendation of “Hold” by the seventeen ratings firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, thirteen have issued a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $31.7143.

Several analysts have issued reports on HIMS shares. Zacks Research upgraded Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th. TD Cowen lowered their price target on Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating for the company in a report on Friday, March 27th. Needham & Company LLC raised Hims & Hers Health from a “hold” rating to a “buy” rating and set a $30.00 price target on the stock in a research report on Monday, March 9th. Bank of America upgraded Hims & Hers Health from an “underperform” rating to a “neutral” rating and raised their price objective for the stock from $12.50 to $23.00 in a research note on Tuesday, March 10th. Finally, Citigroup raised shares of Hims & Hers Health from a “sell” rating to a “neutral” rating and lifted their price objective for the stock from $13.25 to $24.00 in a report on Tuesday, March 10th.

Insider Buying and Selling at Hims & Hers Health

In other news, insider Irene Becklund sold 5,529 shares of Hims & Hers Health stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total value of $136,511.01. Following the completion of the transaction, the insider directly owned 8,752 shares of the company’s stock, valued at approximately $216,086.88. The trade was a 38.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Soleil Boughton sold 4,812 shares of the stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total transaction of $118,808.28. Following the sale, the insider owned 308,831 shares in the company, valued at approximately $7,625,037.39. This trade represents a 1.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 134,984 shares of company stock valued at $3,458,041. Corporate insiders own 13.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

A number of institutional investors and hedge funds have recently made changes to their positions in HIMS. Vanguard Group Inc. boosted its position in Hims & Hers Health by 7.2% during the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after purchasing an additional 1,407,651 shares during the period. Capital World Investors increased its position in Hims & Hers Health by 1.2% in the third quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock worth $1,065,399,000 after buying an additional 223,892 shares during the period. Farallon Capital Management LLC lifted its stake in Hims & Hers Health by 30.8% in the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after buying an additional 2,533,271 shares during the last quarter. State Street Corp boosted its holdings in shares of Hims & Hers Health by 1.8% during the fourth quarter. State Street Corp now owns 7,305,525 shares of the company’s stock valued at $237,210,000 after acquiring an additional 132,311 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Hims & Hers Health by 12.4% during the fourth quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock valued at $183,485,000 after acquiring an additional 608,950 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Price Performance

HIMS opened at $19.16 on Friday. The company has a 50-day moving average of $20.67 and a 200-day moving average of $34.65. The company has a market capitalization of $4.37 billion, a P/E ratio of 37.56, a PEG ratio of 2.31 and a beta of 2.32. Hims & Hers Health has a 1-year low of $13.74 and a 1-year high of $70.43. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.70 and a current ratio of 1.90.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, February 23rd. The company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.02 by $0.06. The business had revenue of $617.82 million for the quarter, compared to analysts’ expectations of $619.48 million. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The company’s quarterly revenue was up 28.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.11 earnings per share. Equities analysts expect that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.